Recent developments for BullFrog AI include the unveiling of new AI capabilities, product launches, strategic collaborations, and leadership appointments, reflecting ongoing efforts to advance its AI-driven drug discovery platform and address Nasdaq listing compliance challenges.

• BullFrog AI announced the unveiling of a new precision AI capability in February 2026, enhancing its drug discovery platform [N1].
• In July 2025, the company launched bfLEAP™ to revolutionize drug discovery and improve clinical trial success rates [N3].
• BullFrog AI announced a strategic collaboration with Sygnature Discovery in June 2025 to enhance drug development capabilities [N5].
• Dr. Juan Felipe Beltrán was featured as a speaker at an XTalks webinar on AI in bioinformatics in June 2025, highlighting the company’s expertise [N4].
• The company reflected on milestones and progress in 2024 and outlined its vision for 2025, emphasizing AI-driven solution commercialization [N7][N8].

BullFrog AI’s proprietary AI/ML platform bfLEAP™ offers a potentially disruptive approach to drug development by enabling more precise analysis of complex biomedical data, which could improve clinical trial success rates and reduce development costs. The company’s strategic collaborations and exclusive licenses for drug candidates in oncology and other indications provide a foundation for advancing therapeutics using its technology. The planned launch of a scenario-based decision engine and ongoing product innovation demonstrate active development of its AI capabilities. BullFrog AI’s liquidity position as of December 31, 2025, with cash and current assets exceeding current liabilities, supports continued operations and development activities. The company’s focus on fee-for-service contracts, collaborative arrangements, and drug asset enhancement offers multiple potential revenue streams. If the company successfully navigates Nasdaq listing compliance challenges and secures additional financing, it could further develop its platform and drug pipeline, potentially creating value through improved drug repositioning and precision medicine applications.

BullFrog AI operates in a highly competitive and rapidly evolving AI-driven biopharmaceutical sector with significant technological and regulatory challenges. The company has a limited operating history, has not yet commercialized any drug, and reported significant net losses and accumulated deficits, raising substantial doubt about its ability to continue as a going concern without additional financing. Nasdaq listing compliance issues related to minimum stockholders’ equity and bid price requirements pose risks to its market presence and liquidity. The company’s reliance on licensing agreements with milestone and royalty obligations could impose financial burdens if drug candidates do not progress successfully. The AI/ML platform’s effectiveness in improving drug development outcomes remains to be fully demonstrated in commercial settings. Additionally, the company’s small workforce and dependence on strategic partnerships may limit its operational capacity. Failure to secure sufficient capital or regulatory approvals could materially impair its business prospects.

BullFrog AI’s competitive advantages stem from its proprietary bfLEAP™ AI/ML platform, which is derived from advanced technology developed at Johns Hopkins University Applied Physics Laboratory. The platform’s ability to handle highly imbalanced, complex, and incomplete biomedical data sets with both supervised and unsupervised machine learning algorithms provides scalability and precision that the company asserts surpasses many open-source alternatives. The bfLEAP™ platform’s proprietary algorithms and intellectual property, protected through exclusive licenses and royalty agreements, create barriers to entry for competitors relying on open-source tools. Additionally, BullFrog AI’s strategic collaborations with leading research institutions and exclusive licensing of drug candidates provide access to unique data and assets. The company’s focus on precision medicine and its integrated AI-powered data preparation and bioinformatics platforms further enhance its ability to deliver actionable insights across the drug development lifecycle. However, the company is still in early stages with no commercialized drugs, which limits the current strength of its moat.

• Nasdaq Listing Compliance Risk: The company has received notices of non-compliance with Nasdaq listing rules related to minimum stockholders’ equity and minimum bid price requirements. Failure to regain compliance could result in delisting, adversely affecting stock liquidity, market price, and ability to raise capital.
• Financial Sustainability Risk: BullFrog AI has incurred significant net losses and has substantial accumulated deficits, with limited revenue generation. There is substantial doubt about its ability to continue as a going concern without additional financing, which may not be available on favorable terms.
• Regulatory and Clinical Development Risk: The company’s drug candidates are in early stages, and clinical trials are required to validate AI-driven repositioning strategies. Regulatory approvals are uncertain and may delay or prevent commercialization.
• Technology and Competitive Risk: The AI/ML platform operates in a competitive environment with rapid technological change. The proprietary algorithms may face challenges from open-source alternatives or new entrants, and the platform’s clinical utility is not yet fully proven.
• Intellectual Property Risk: The company relies on licenses from universities and third parties with milestone and royalty obligations. Failure to maintain these licenses or protect intellectual property could impair competitive advantage.

• BullFrog AI Holdings, Inc. is a digital biopharmaceutical company incorporated in Nevada in 2020, operating through its wholly owned subsidiary BullFrog AI, Inc.
• The company develops and applies an AI/ML platform called bfLEAP™ for analysis of preclinical and clinical data to improve drug development success rates and reduce costs.
• bfLEAP™ is derived from technology developed at Johns Hopkins University Applied Physics Laboratory (JHU-APL) and uses both supervised and unsupervised machine learning to analyze complex, high-dimensional biomedical data.
• BullFrog AI also offers BullFrog Data Networks™ and bfPREP™ platforms for bioinformatics data integration and preparation, targeting biotechnology and pharmaceutical companies.
• The company’s business model includes contract services (fee-for-service AI/ML analysis), collaborative arrangements with biotech/pharma companies, and acquisition of rights to drug candidates, especially those that failed late-stage trials, to reposition them using AI insights.
• BullFrog AI holds exclusive worldwide licenses for drug candidates targeting glioblastoma, hepatocellular carcinoma, and other cancers, including siRNA therapeutics and improved formulations of mebendazole.
• The company has not yet commercialized any drug; one licensed candidate completed Phase I trials, and another is in preclinical stages.
• BullFrog AI had approximately $2.18 million in cash and cash equivalents and $2.58 million in current assets as of December 31, 2025, with current liabilities of $672,022, resulting in a current ratio of 3.85 and cash ratio of 3.25.
• For the fiscal year ended December 31, 2025, the company reported revenue of $116,670 and a net loss of $6,498,068, with basic and diluted EPS of -$0.63 per share.
• The company faces Nasdaq listing compliance challenges related to minimum stockholders’ equity and minimum bid price requirements, with ongoing efforts to regain compliance including a potential reverse stock split.
• BullFrog AI has strategic collaborations with research institutions and biotech companies, including a partnership with Sygnature Discovery and a data use agreement with the Lieber Institute for Brain Development.
• The company plans to launch a new AI-powered scenario-based decision engine in March 2026 to support complex decision-making in drug development and biomedical research.
• BullFrog AI’s CEO and management team have been active in industry events and webinars, emphasizing AI-driven solution commercialization as a focus for 2025.
• The company operates with a small workforce of 9 full-time employees and 8 part-time employees, advisors, and consultants as of December 31, 2025.
• BullFrog AI’s AI/ML platform bfLEAP™ is positioned as scalable, capable of handling incomplete data, and proprietary, with competitive advantages over open-source algorithms.
• The company’s financial disclosures note significant losses and substantial doubt about its ability to continue as a going concern without additional financing.
• BullFrog AI’s licensing agreements with JHU and George Washington University include royalty and milestone payment obligations contingent on clinical and commercial progress.
• The company’s strategy includes acquiring rights to failed or developing drugs, using AI to identify responsive patient profiles, conducting clinical trials, and divesting assets to larger pharmaceutical companies.
• BullFrog AI’s recent news includes product launches, strategic collaborations, and participation in industry symposiums, reflecting ongoing development and commercialization efforts.